T
Toshiyuki Sawa
Publications - 43
Citations - 2438
Toshiyuki Sawa is an academic researcher. The author has contributed to research in topics: Lung cancer & Carboplatin. The author has an hindex of 16, co-authored 41 publications receiving 2212 citations.
Papers
More filters
Journal Article
Polymorphisms of UDP-Glucuronosyltransferase Gene and Irinotecan Toxicity: A Pharmacogenetic Analysis
Yuichi Ando,Hideo Saka,M. Ando,Toshiyuki Sawa,Kei Muro,Hiroshi Ueoka,Akira Yokoyama,Soh Saitoh,Kaoru Shimokata,Yoshinori Hasegawa +9 more
TL;DR: It is suggested that determination of the UGT1A1 genotypes might be clinically useful for predicting severe toxicity by irinotecan in cancer patients and warrants a prospective trial to corroborate the usefulness of gene diagnosis of UGT2A1 polymorphisms prior tb irinOTecan chemotherapy.
Journal ArticleDOI
Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105
Nobuyuki Yamamoto,Kazuhiko Nakagawa,Yasumasa Nishimura,Kayoko Tsujino,Miyako Satouchi,Shinzoh Kudo,Toyoaki Hida,Masaaki Kawahara,Koji Takeda,Nobuyuki Katakami,Toshiyuki Sawa,Soichiro Yokota,Takashi Seto,Fumio Imamura,Hideo Saka,Yasuo Iwamoto,Hiroshi Semba,Yasutaka Chiba,Hisao Uejima,Masahiro Fukuoka +19 more
TL;DR: Arm C was equally efficacious and exhibited a more favorable toxicity profile among three arms and should be considered a standard regimen in the management of locally advanced unresectable NSCLC.
Journal ArticleDOI
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)
Shinji Atagi,Masaaki Kawahara,Akira Yokoyama,Hiroaki Okamoto,Nobuyuki Yamamoto,Yuichiro Ohe,Toshiyuki Sawa,Satoshi Ishikura,Taro Shibata,Haruhiko Fukuda,Nagahiro Saijo,Tomohide Tamura +11 more
TL;DR: For a select group of elderly patients with locally advanced NSCLC, combination chemoradiotherapy provides a clinically significant benefit over radiotherapy alone, and should be considered for this population.
Journal ArticleDOI
Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203)
Koji Takeda,Toyoaki Hida,Tosiya Sato,Masahiko Ando,Takashi Seto,Miyako Satouchi,Yukito Ichinose,Nobuyuki Katakami,Nobuyuki Yamamoto,Shinzoh Kudoh,Jiichiro Sasaki,Kaoru Matsui,Koichi Takayama,Tatsuhiko Kashii,Yasuo Iwamoto,Toshiyuki Sawa,Isamu Okamoto,Takayasu Kurata,Kazuhiko Nakagawa,Masahiro Fukuoka +19 more
TL;DR: The exploratory subset analyses demonstrate a possible survival prolongation for sequential therapy of gefitinib, especially for patients with adenocarcinoma, as the primary end point of OS in patients with NSCLC was failed.
Journal ArticleDOI
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: Results of a west Japan oncology group study
Isamu Okamoto,Hiroshige Yoshioka,Satoshi Morita,Masahiko Ando,Koji Takeda,Takashi Seto,Nobuyuki Yamamoto,Hideo Saka,Kazuhiro Asami,Tomonori Hirashima,Shinzoh Kudoh,Miyako Satouchi,Norihiko Ikeda,Yasuo Iwamoto,Toshiyuki Sawa,Masaki Miyazaki,Kenji Tamura,Takayasu Kurata,Masahiro Fukuoka,Kazuhiko Nakagawa +19 more
TL;DR: Oral S-1 with carboplatin was noninferior in terms of OS compared withcarboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option.